FOR IMMEDIATE RELEASE


Contacts:
Marc Panoff, CFO              Garth Russell / Todd Fromer
Nephros, Inc.                 KCSA Worldwide
Tel: 212-781-5113             212-896-1250 / 212-896-1215


           NEPHROS, INC. TO RECEIVE U.S. PATENT FOR OLpur(TM) H2H(TM)
                                       ---

NEW YORK, July 8, 2005 -- Nephros, Inc. (AMEX: NEP) announced today it has
received confirmation from the United States Patent and Trademark Office that it
will be receiving a patent on its OLpur(TM) H2H(TM) product, which incorporates
proprietary technologies that allow users of conventional hemodialysis machines
to perform convective-based hemodiafiltration (HDF) therapies with on-line
ultra-pure substitution fluid. Nephros believes that its OLpur(TM) H2H(TM)
product will permit it to introduce on-line HDF therapy to the U.S. dialysis
market without the need for clinics to replace their existing hemodialysis
machines. The OLpur(TM) H2H(TM) has been designed to operate with the most
common hemodialysis machines. The FDA has not yet approved HDF with on-line
substitution fluid or use of the OLpur(TM) H2H(TM) or OLpur(TM) MD190 products.

The application from which the patent will issue is serial No. 10/072,464,
entitled "Method and Apparatus for a Hemodiafiltration Delivery Module."

Nephros believes its H2H(TM) technology can significantly reduce the cost of
providing HDF compared to traditional methods of using terminally sterilized
fluids for these applications. "Hemodiafiltration with on-line substitution
fluid is not currently available in the U.S.; this patent allowance gives us the
exclusive right to use the OLpur(TM) H2H(TM) product to open up the U.S. market
to HDF. Together with our premier OLpur(TM) MD190 mid-dilution hemodiafilter, we
believe we will be in a position to provide the best therapy available to the
more than 1,000,000 patients with end-stage renal disease worldwide. We believe
our product line will offer patients a unique combination to gain potentially
substantial therapeutic benefits, while clinics can use their current dialysis
equipment in order to achieve these marked benefits with potentially sizeable
associated savings," said Norman Barta, Nephros CEO.

About Nephros, Inc.
Nephros, Inc., headquartered in New York, is a medical device company developing
and marketing products designed to improve the quality of life for the end-stage
renal disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider. ESRD is a disease state characterized by
the irreversible loss of kidney function. Nephros believes that its products
remove a range of harmful substances more effectively, and more
cost-effectively, than existing treatment methods; particularly with respect to
substances known collectively as "middle molecules," due to their molecular
weight, that have been found to contribute to such conditions as carpal tunnel
syndrome, dialysis related amyloidosis, degenerative bone disease, and
ultimately, to mortality in the ESRD patient.




Forward-Looking Statements
This news release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such statements may include statements regarding the efficacy and intended use
of Nephros's technologies under development, the timelines for bringing such
products to market and the availability of funding sources for continued
development of such products and other statements that are not historical facts,
including statements which may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. For such statements,
we claim the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based
on certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of Nephros. Actual results
may differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks that: (i)
potential products that appeared promising to Nephros in early research or
clinical trials may not demonstrate efficacy or safety in subsequent
pre-clinical or clinical trials; (ii) Nephros may not obtain appropriate or
necessary governmental approvals; (iii) product orders may be cancelled,
patients currently using Nephros's products may cease to do so and patients
expected to begin using Nephros's products may not; (iv) Nephros may not be able
to obtain funding if and when needed; (v) HDF therapy may not be accepted in the
United States and/or Nephros's technology and products may not be accepted in
target markets; (vi) Nephros may not be able to sell its products at competitive
prices or profitably; and (vii) the patent may not enable Nephros to secure or
enforce adequate legal protection for its products. More detailed information
about Nephros and the risk factors that may affect the realization of
forward-looking statements is set forth in Nephros's filings with the Securities
and Exchange Commission, including Nephros's Annual Report on Form 10-KSB filed
with the SEC for the fiscal year ended December 31, 2004 and its Quarterly
Report on Form 10-QSB filed with the SEC for the fiscal quarter ended March 31,
2005. Investors and security holders are urged to read those documents free of
charge on the SEC's web site at www.sec.gov. Nephros does not undertake to
publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.


                                       # # #